Falsolieva 250mg

Folsolieva 250mg Injection contains fulvestrant as its active ingredient. This antineoplastic medication is classified as an estrogen receptor antagonist. Estrogen, a female sex hormone, can sometimes contribute to the development of breast cancer. This medication is utilized on its own to treat postmenopausal women diagnosed with a specific type of breast cancer known as estrogen receptor-positive breast cancer, which may be locally advanced or have metastasized to other areas of the body.

Additionally, it is prescribed in conjunction with other anti-cancer drugs for women with certain forms of breast cancer referred to as hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, which is either locally advanced or has spread to other regions of the body.

This injection should not be administered if you are allergic to fulvestrant or any of its components, are pregnant or nursing, or have serious liver issues. Prior to starting treatment, it is essential to inform your healthcare provider if you have kidney or liver conditions, bone disorders, bleeding issues, or heart diseases.

Folsolieva 250mg Injection is not suitable for children and adolescents under the age of 18. Notify your doctor if you experience any allergic reactions, such as swelling of the face, lips, tongue, or throat, following the injection.

Common side effects associated with Folsolieva 250mg Injection include pain or inflammation at the injection site, abnormal liver enzyme levels, nausea, headaches, cough, fatigue, joint and muscle discomfort, hot flashes, hair loss, and skin rashes. Your physician may recommend specific blood tests during your treatment with this injection. There is a potential increase in the risk of bleeding and liver failure with this medication. Women of reproductive age should employ effective contraception during treatment and for two years following the final dose.